Key facts
- ReGenics (Oslo)’s last known valuation is $13.5M (May 2025).
- It has raised $5.2M; the latest was Accelerator/Incubator in Feb 2026.
- Notable investors include Aleap, IS Funds, ShareLab Incubator.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ReGenics (Oslo)
- ·The full record, as it builds
Funding rounds
No funding rounds for ReGenics (Oslo) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ReGenics (Oslo)
Operator of a biotechnology company developing a range of wound care products. The company offers products for target diagnoses including burns, diabetic wounds, chronic wounds, and enzymatic wound debridement.
- Sector
- Healthcare
- HQ
- Oslo, Norway
- Founded
- 2000
- Employees
- 7
- Website
- regenics.no/
- Ownership
- Privately Held (backing)
ReGenics (Oslo) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReGenics (Oslo) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReGenics (Oslo) in its N-PORT filings yet. We sweep new filings monthly.